耐受原性树突状细胞作为免疫性血小板减少症治疗的靶点。
Tolerogenic dendritic cells as a target for the therapy of immune thrombocytopenia.
机构信息
Shandong University, Shandong, China.
出版信息
Clin Appl Thromb Hemost. 2012 Sep;18(5):469-75. doi: 10.1177/1076029612438612. Epub 2012 Mar 2.
Immune thrombocytopenia (ITP) is an autoimmune disease in which platelets are destroyed by special antiplatelet autoantibodies produced by B cells. Dendritic cells (DCs) are professional antigen-presenting cells involved in humoral immunity and cellular immunity and among them DCs that induce autoimmune tolerance are called tolerogenic DCs (tDCs). As a promising immunotherapeutic strategy for ITP, tDCs have received increasing attention. In this review, we describe the significant role of DCs in regulating autoimmune balances, introduce the manipulation strategies to generate tDCs, summarize recent progress on the experimental application of tDCs for ITP therapy, and finally discuss the perspectives of tolerogenic vaccination for ITP treatment in the clinic.
免疫性血小板减少症 (ITP) 是一种自身免疫性疾病,其中血小板被 B 细胞产生的特殊抗血小板自身抗体破坏。树突状细胞 (DCs) 是参与体液免疫和细胞免疫的专业抗原提呈细胞,其中诱导自身免疫耐受的 DC 称为耐受原性 DCs (tDCs)。作为 ITP 的一种有前途的免疫治疗策略,tDCs 受到了越来越多的关注。在这篇综述中,我们描述了 DCs 在调节自身免疫平衡中的重要作用,介绍了产生 tDCs 的操作策略,总结了 tDCs 在 ITP 治疗中的实验应用的最新进展,最后讨论了耐受原性疫苗在 ITP 治疗中的临床应用前景。